自體免疫疾病合作與授權交易（2016-2024）

本報告審查了2016年至2024年期間與自體免疫疾病相關的905 份合作和授權交易，並審查了交易總數、財務交易條款以及交易活躍的前25 家公司的趨勢。

本報告涵蓋以下自體免疫疾病：

• 多發性硬化症、不寧腿症候群、皮膚炎、濕疹、掉髮、牛皮癬、乳糜瀉、發炎性腸道疾病、克隆氏症、潰瘍性結腸炎、腎絲球腎炎、子宮內膜異位症、免疫系統血小板減少性紫斑症、嗜中性白血球減少症、移植物抗宿主疾病、硬皮症、系統性紅斑狼瘡、愛迪生氏病、第一型糖尿病、僵直性脊椎炎、幼年關節炎、乾癬性關節炎、類風濕性關節炎、小徑發炎、發作性睡病、慢性阻塞性肺病、特發性肺纖維化、結節性多發性動脈炎、梅尼爾氏症等。

主な利點

本報告為讀者提供了以下主要好處：

• 了解2016年以來的合約趨勢
• 查看業務夥伴交易
• 基準分析：確定交易的市場價值
• 財務条件
• 交易清單：依公司名稱（A-Z）、治療領域和技術類型
• 主要交易（金額基礎）
• 最活躍的談判者
• 每筆交易的資產識別和交易條件
• 取得合約文件：深入了解交易結構
• 實質審查：評估擬議交易條款對合作夥伴公司的適用性
• 節省數百小時的研究時間

合約分析允許實質審查：

• 授予/選擇了哪些權利？
• 合約授予了哪些權利？
• 授予哪些類型的專有權？
• 合約的付款結構為
• 如何審核銷售和付款？
• 合約期限為
• 合約的主要條款是如何定義的？
• 如何對待和擁有知識產權？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和發布？
• 如何解決爭議？
• 什麼情況下可以取消合約？
• 如果所有者發生變化會怎樣？
• 已就哪些從屬許可或分包條款達成協議？
• 公司需要哪些樣板條款？
• 哪些樣板條款看起來有所不同，取決於合作夥伴和交易類型？
• 每家公司對合約法擁有哪些管轄權？

目次

執行摘要

第1章 簡介

第2章 自體免疫疾病貿易趨勢

• 自體免疫疾病相關交易：年度趨勢
• 自體免疫疾病相關交易：依交易類型
• 自體免疫疾病相關交易：依行業分類
• 自體免疫疾病相關交易：依發展階段
• 自體免疫疾病相關交易：依技術類型

第3章 自體免疫疾病：金融交易條款

• 財務條款的揭露
• 標題金額
• 預付款
• 里程碑
• 特許權使用費率

第4章 自體免疫疾病：主要客戶與交易

• 交易中最活躍的談判者
• 最活躍的交易談判者名單
• 主要交易：依交易金額

第5章 自體免疫疾病交易：合約文件目錄

• 合約文件：可用

第6章 自己免疫疾患取引：治療標的別

• 自體免疫疾病交易：依治療目標分類
• 交易目錄
• 交易目錄：依公司（2016-2024年）
• 貿易名錄：依技術類型（2016-2024年）
• 交易類型的定義
• 關於Biopharma Research Ltd
• 目前的合作關係
• 當前合約
• Current Partnering 最近的報告標題

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 905 autoimmune deals from 2016 to 2024.

The report includes coverage of the following autoimmune diseases:

• Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
• The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.
• Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
• Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.
• The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
• In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse autoimmune collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.

Autoimmune Collaboration and Licensing Deals includes:

• Trends in autoimmune dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of autoimmune deal records covering pharmaceutical and biotechnology
• The leading autoimmune deals by value
• Most active autoimmune licensing dealmakers

In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

• 2.1. Introduction
• 2.2. Autoimmune deals over the years
• 2.3. Autoimmune deals by deal type
• 2.4. Autoimmune deals by industry sector
• 2.5. Autoimmune deals by stage of development
• 2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

• 3.1. Introduction
• 3.2. Disclosed financials terms for autoimmune deals
• 3.3. Autoimmune deal headline values
• 3.4. Autoimmune deal upfront payments
• 3.5. Autoimmune deal milestone payments
• 3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

• 4.1. Introduction
• 4.2. Most active in autoimmune dealmaking
• 4.3. List of most active dealmakers in autoimmune
• 4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

• 5.1. Introduction
• 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by autoimmune therapeutic target
• Deal Directory
• Deal Directory - Autoimmune deals by company A-Z 2016 to 2024
• Deal Directory - Autoimmune deals by technology type 2016 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Autoimmune deals since 2016
• Figure 2: Autoimmune deals by deal type since 2016
• Figure 3: Autoimmune deals by industry sector since 2016
• Figure 4: Autoimmune deals by stage of development since 2016
• Figure 5: Autoimmune deals by technology type since 2016
• Figure 6: Autoimmune deals with a headline value
• Figure 7: Autoimmune deals with upfront payment values
• Figure 8: Autoimmune deals with milestone payment
• Figure 9: Autoimmune deals with royalty rates
• Figure 10: Active autoimmune dealmaking activity since 2016
• Figure 11: Top autoimmune deals by value since 2016